The benefit of a legal entity is that the entity carries insurance and provides a single point of authority for enforcement should the terms of the contract be breached.
Lawmakers in Maryland and California want to ensure that any college claiming to be nonprofit is not operating to the benefit of a for-profit entity.
The use of eminent domain for the benefit of private entities is a hot topic nowadays.
Can you explain the benefit of putting it in an entity or a trust?
An activity node represents the activity of an entity or an entity pool but not the entities themselves.
Trump's lawyers argued that the term "publicly held" applied to the word "corporation," but not to "other entity". To ensure that profit earned through the lease would fall to the "general benefit" of this "other entity," the lawyers altered the structure of the Trump-owned limited liability companies involved in the hotel.
What Are the Important Properties of an Entity?
Preet Bharara, the United States attorney, who announced the charges with George Venizelos, the head of the Federal Bureau of Investigation's New York office, said the defendants had "colluded with representatives from a Chinese government entity and a direct competitor of the university for which they worked to illegally acquire N.I.H.-funded research for the benefit of those entities".
The three had "colluded with representatives from a Chinese government entity and a direct competitor of the university for which they worked to illegally acquire N.I.H.-funded research for the benefit of those entities," charged U.S. Attorney Preet Bharara, as quoted by The New York Times.
Zarrab was arrested last year at age 33 when he visited Miami and jailed, charged for conducting hundreds of millions of dollars in transactions through Turkey and the United Arab Emirates for the benefit of sanctioned Iranian entities and laundering the proceeds of illegal activity.
This review examines the use of PROs as both primary and nonprimary endpoints in support of demonstration of treatment benefit of new molecular entities (NMEs) and biologic license applications (BLAs) in the United States in the years 2000 to 2012.
